Drilldown: Medicines
Medicines > fda max 
:
4 g/d or
600 mg/d or
Formulation-specific (e.g., 145 mg/d Tricor, 200 mg/d Lipofen)
:
4 g/d or
600 mg/d or
Formulation-specific (e.g., 145 mg/d Tricor, 200 mg/d Lipofen) Use the filters below to narrow your results.
generic:
brand:
classes:
[[:Category:Antitussives|Antitussive]] (1) ·
[[:Category:Beta-lactam_antibiotics|β-lactam antibiotic]] (2) ·
[[:Category:Cephalosporins|Cephalosporin (first-generation)]] (1) ·
[[:Category:Cephalosporins|Cephalosporin (third-generation)]] (1) ·
[[:Category:Fibrates|Fibrate]] (1) ·
[[:Category:Lipid-lowering_agents|Lipid-lowering agent]] (3) ·
[[:Category:Omega-3_fatty_acids|Omega-3 fatty acid]] (2) ·
[[:Category:PPAR_alpha_agonists|PPAR-α agonist]] (1)
mechanism:
None (3) ·
'"`UNIQ--vote-00000015-QINU`"' Pediatric ingestion (capsule chewed or punctured) releases the free local anesthetic and causes seizures, cardiac arrhythmia, and death'"`UNIQ--ref-00000016-QINU`"'. (1) ·
'"`UNIQ--vote-0000004E-QINU`"' The EPA+DHA mix is biochemically and clinically distinct from icosapent ethyl'"`UNIQ--ref-0000004F-QINU`"'. (1) ·
'"`UNIQ--vote-000004A9-QINU`"' Modest HDL rise; LDL effects mixed. Renally cleared; combination with statin carries elevated myopathy risk (greater for gemfibrozil than fenofibrate, but caution still warranted)'"`UNIQ--ref-000004AA-QINU`"'. (1)
uses:
'"`UNIQ--vote-00000017-QINU`"' (1) ·
'"`UNIQ--vote-00000050-QINU`"' (1) ·
'"`UNIQ--vote-000004AB-QINU`"', '"`UNIQ--vote-000004AC-QINU`"' (1) ·
'"`UNIQ--vote-000004ED-QINU`"', '"`UNIQ--vote-000004EE-QINU`"', '"`UNIQ--vote-000004EF-QINU`"', '"`UNIQ--vote-000004F0-QINU`"', '"`UNIQ--vote-000004F1-QINU`"' (1) ·
'"`UNIQ--vote-000009DF-QINU`"', '"`UNIQ--vote-000009E0-QINU`"', '"`UNIQ--vote-000009E1-QINU`"', '"`UNIQ--vote-000009E2-QINU`"', '"`UNIQ--vote-000009E3-QINU`"' (1) ·
'"`UNIQ--vote-000013CF-QINU`"', '"`UNIQ--vote-000013D0-QINU`"' (1)
starting dose:
100-200 mg PO TID (max 600 mg/d) (1) ·
2 g PO BID with meals (4 g/d total) (1) ·
300 mg PO BID, or 600 mg PO once daily, ×5-10 days; pediatric 14 mg/kg/d (1) ·
4 g PO daily (as 4 x 1 g capsules once daily, or 2 capsules BID) (1) ·
500 mg PO every 6 hours, or 250 mg every 6 hours for mild infections (1) ·
Varies by salt form and brand; e.g., Tricor 145 mg PO daily; reduce to 48 mg in renal impairment (1)
preparations:
0.5 g, 1 g capsules (1) ·
1 g soft gelatin capsules containing ~465 mg EPA + ~375 mg DHA as ethyl esters (1) ·
100, 150, 200 mg liquid-filled capsules ("perles") (1) ·
250 mg, 500 mg, 750 mg capsules; 250 mg/5 mL, 125 mg/5 mL suspension; tablets (1) ·
300 mg capsules; 125, 250 mg/5 mL suspension (1) ·
Multiple non-bioequivalent fenofibrate and fenofibric acid formulations: 48-200 mg (1)
fda max: (Click arrow to add another value)
routes:
onset:
duration:
halflife:
Not well characterized; tissue incorporation over weeks'"`UNIQ--ref-00000051-QINU`"' (1) ·
Not well characterized'"`UNIQ--ref-00000018-QINU`"' (1) ·
~1 hour'"`UNIQ--ref-000004F2-QINU`"' (1) ·
~1.7 hours'"`UNIQ--ref-000009E4-QINU`"' (1) ·
~20 hours (fenofibric acid, the active metabolite)'"`UNIQ--ref-000004AD-QINU`"' (1) ·
~89 hours (EPA, the active metabolite)'"`UNIQ--ref-000013D1-QINU`"' (1)
bioavailability:
16-21% capsule, 25% suspension (oral; iron and antacids reduce absorption substantially)'"`UNIQ--ref-000009E5-QINU`"' (1) ·
90% (oral; food delays but does not reduce absorption)'"`UNIQ--ref-000004F3-QINU`"' (1) ·
Improved with food'"`UNIQ--ref-00000052-QINU`"' (1) ·
Increased with food (varies by formulation; the micronized and nanocrystal forms are less food-dependent)'"`UNIQ--ref-000004AE-QINU`"' (1) ·
Not well characterized'"`UNIQ--ref-00000019-QINU`"' (1) ·
Substantially improved with high-fat meal; take with food'"`UNIQ--ref-000013D2-QINU`"' (1)
pregnancy:
Generally considered safe in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; generally avoided unless triglyceride pancreatitis risk is high.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; animal reproductive studies not conducted<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 6 results in range #1 to #6.